Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Akums Drugs and Pharmaceuticals Limited

AKUMS · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹731.70

−₹9.35 (−1.26%)(1D)

₹409.3052 Week Range₹838.80

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

60/100

Valuation

35/100

Quality

44/100

Growth

54/100

Health

99/100

Momentum

88/100

Valuation
35
Quality
44
Growth
54
Health
99
Momentum
88

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Akums Drugs and Pharmaceuticals Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹731.7

Market cap

₹11,309 Cr

P/E ratio

38.41

P/B ratio

3.41

Dividend yield

Not available

ROE

Not available

RSI 14

46.98

1Y return

Not available

Akums Drugs and Pharmaceuticals Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Akums Drugs and Pharmaceuticals Limited (AKUMS) stock page cover?

Akums Drugs and Pharmaceuticals Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for AKUMS?

Akums Drugs and Pharmaceuticals Limited is currently shown with a delayed price near ₹731.7, P/E 38.41.

Does the AKUMS page provide investment advice?

No. The AKUMS page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

SUDEEPPHRM

Sudeep Pharma Limited · Healthcare

STAR

Strides Pharma Science Limited · Healthcare

VIYASH

Viyash Scientific Limited · Healthcare

Eliminating Look-Ahead Bias in Indian Fundamental Backtests

Understand why using quarter-end dates (like March 31) invalidates fundamental backtests. Learn how Anvest enforces official SEBI filing delays.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Akums Drugs and Pharmaceuticals Limited manufactures pharmaceutical formulations, contributing 100% of its total turnover. The company operates 19 locations, including 14 national offices.

Drug Manufacturers - Specialty & GenericFounded:2004CEO/MD:Sanjeev Jain, Sandeep Jain (Joint Managing Directors)HQ:Haridwar, Uttarakhand

Business at a Glance

Additionally, it provides contract manufacturing services to other pharmaceutical companies, leveraging its manufacturing capabilities and expertise to produce drugs on their behalf.

What Looks Strong

Financial highlights are being recalculated.

What to Watch

Financial highlights are being recalculated.

Segment revenue, FY26 (consolidated, as filed): CDMO 80%; Domestic Branded Formulations 10%; API 4%; International Branded Formulations 3%; Trade Generics 2%.
Share of segment profit before interest and tax, FY26: CDMO 73%; Domestic Branded Formulations 19%; International Branded Formulations 8%. API made a segment loss of ₹57.7 cr (and 1 more).
The company generates revenue by developing, manufacturing, and marketing a diverse portfolio of generic and specialty pharmaceutical products.